NCT06259552View on ClinicalTrials.gov

A Study of SPX-303, a Bispecific Antibody Targeting LILRB2 and PD-L1 in Patients With Solid Tumors

PHASE1RecruitingINTERVENTIONAL
Enrollment

232

Participants

Timeline

Start Date

March 20, 2024

Primary Completion Date

September 30, 2027

Study Completion Date

September 30, 2027

Conditions
Solid TumorHNSCCRCCCRC
Interventions
BIOLOGICAL

SPX- 303 Injection, a bispecific anti-LILRB2 / anti-PD-L1 Antibody

SPX- 303 Injection

Trial Locations (4)

32224

RECRUITING

Mayo Clinic Florida, Jacksonville

55905

RECRUITING

Mayo Clinic Rochester, Rochester

85054

RECRUITING

Mayo Clinic Arizona, Phoenix

85258

RECRUITING

HonorHealth Research and Innovation Institute, Scottsdale

All Listed Sponsors
lead

SparX Biotech(Jiangsu) Co., Ltd.

OTHER